Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:2608-2614
doi: 10.1161/hc4601.099402
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, D.
Right arrow Articles by Nattel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, D.
Right arrow Articles by Nattel, S.
Related Collections
Right arrow Congestive
Right arrow Remodeling
Right arrow Cardiovascular Pharmacology
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2001;104:2608.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure

Danshi Li, MD PhD; Kaori Shinagawa, MD; Li Pang, MD; Tack Ki Leung, MD; Sophie Cardin, BSc; Zhiguo Wang, PhD; Stanley Nattel, MD

From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.

Correspondence to Stanley Nattel, 5000 Belanger St E, Montreal, Quebec, Canada H1T 1C8. E-mail nattel{at}icm.umontreal.ca

Background Atrial structural remodeling creates a substrate for atrial fibrillation (AF), but the underlying signal transduction mechanisms are unknown. This study assessed the effects of ACE inhibition on arrhythmogenic atrial remodeling and associated mitogen-activated protein kinase (MAPK) changes in a dog model of congestive heart failure (CHF).

Methods and Results Dogs were subjected to various durations of ventricular tachypacing (VTP, 220 to 240 bpm) in the presence or absence of oral enalapril 2 mg · kg-1 · d-1. VTP for 5 weeks induced CHF, local atrial conduction slowing, and interstitial fibrosis and prolonged atrial burst pacing–induced AF. Atrial angiotensin II concentrations and MAPK expression were increased by tachypacing, with substantial changes in phosphorylated forms of c-Jun N-terminal kinase (JNK), extracellular signal–regulated kinase (ERK), and p38-kinase. Enalapril significantly reduced tachypacing-induced changes in atrial angiotensin II concentrations and ERK expression. Enalapril also attenuated the effects of CHF on atrial conduction (conduction heterogeneity index reduced from 3.1±0.4 to 1.9±0.2 ms/mm, P<0.05), atrial fibrosis (from 11.9±1.1% to 7.5±0.4%, P<0.01), and mean AF duration (from 651±164 to 218±75 seconds, P<0.05). Vasodilator therapy of a separate group of VTP dogs with hydralazine and isosorbide mononitrate did not alter CHF-induced fibrosis or AF promotion.

Conclusions CHF-induced increases in angiotensin II content and MAPK activation contribute to arrhythmogenic atrial structural remodeling. ACE inhibition interferes with signal transduction leading to the AF substrate in CHF and may represent a useful new component to AF therapy.


Key Words: arrhythmia • remodeling • atrium • electrophysiology • heart failure




This article has been cited by other articles:


Home page
CirculationHome page
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Circulation, September 16, 2008; 118(12): 1285 - 1293.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C.-T. Tsai, L.-P. Lai, J.-J. Hwang, J.-L. Lin, and F.-T. Chiang
Molecular Genetics of Atrial Fibrillation
J. Am. Coll. Cardiol., July 22, 2008; 52(4): 241 - 250.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
M. Shimano, Y. Inden, Y. Tsuji, H. Kamiya, T. Uchikawa, R. Shibata, and T. Murohara
Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation
Europace, June 11, 2008; (2008) eun140v1.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
J. L. Serra and M. Bendersky
Review: Atrial fibrillation and renin-angiotensin system
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 215 - 223.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
B. J.J.M. Brundel, L. Ke, A.-J. Dijkhuis, X. Qi, A. Shiroshita-Takeshita, S. Nattel, R. H. Henning, and H. H. Kampinga
Heat shock proteins as molecular targets for intervention in atrial fibrillation
Cardiovasc Res, June 1, 2008; 78(3): 422 - 428.
[Abstract] [Full Text] [PDF]


Home page
Circ Arrhythmia ElectrophysiolHome page
S. Nattel, B. Burstein, and D. Dobrev
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Circ Arrhythmia Electrophysiol, April 1, 2008; 1(1): 62 - 73.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. R. Ehrlich, P. Biliczki, S. H. Hohnloser, and S. Nattel
Atrial-Selective Approaches for the Treatment of Atrial Fibrillation
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 787 - 792.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Burstein and S. Nattel
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 802 - 809.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. C. Roberts-Thomson, I. H. Stevenson, P. M. Kistler, H. M. Haqqani, J. C. Goldblatt, P. Sanders, and J. M. Kalman
Anatomically Determined Functional Conduction Delay in the Posterior Left Atrium: Relationship to Structural Heart Disease
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 856 - 862.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Goette, A. Bukowska, U. Lendeckel, M. Erxleben, M. Hammwohner, D. Strugala, J. Pfeiffenberger, F.-W. Rohl, C. Huth, M. P.A. Ebert, et al.
Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Circulation, February 12, 2008; 117(6): 732 - 742.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C.-T. Tsai, L.-P. Lai, K.-T. Kuo, J.-J. Hwang, C.-S. Hsieh, K.-L. Hsu, C.-D. Tseng, Y.-Z. Tseng, F.-T. Chiang, and J.-L. Lin
Angiotensin II Activates Signal Transducer and Activators of Transcription 3 via Rac1 in Atrial Myocytes and Fibroblasts: Implication for the Therapeutic Effect of Statin in Atrial Structural Remodeling
Circulation, January 22, 2008; 117(3): 344 - 355.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. P. Regan, L. Kiss, G. L. Stump, C. J. McIntyre, D. C. Beshore, N. J. Liverton, C. J. Dinsmore, and J. J. Lynch Jr.
Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 322 - 330.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
F. G. Cosio, E. Aliot, G. L. Botto, H. Heidbuchel, C. J. Geller, P. Kirchhof, J.-C. De Haro, R. Frank, J. P. Villacastin, J. Vijgen, et al.
Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode
Europace, January 1, 2008; 10(1): 21 - 27.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
L. L. Shang, S. Sanyal, A. E. Pfahnl, Z. Jiao, J. Allen, H. Liu, and S. C. Dudley Jr.
NF-{kappa}B-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II
Am J Physiol Cell Physiol, January 1, 2008; 294(1): C372 - C379.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. T. Issac, H. Dokainish, and N. M. Lakkis
Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2021 - 2028.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, C. Dumesnil, A. Nigam, T.-K. Leung, and S. Nattel
Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling
Circulation, November 6, 2007; 116(19): 2101 - 2109.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm
Management of atrial fibrillation in patients with heart failure
Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. G. Platonov
Interatrial conduction in the mechanisms of atrial fibrillation: from anatomy to cardiac signals and new treatment modalities
Europace, November 1, 2007; 9(suppl_6): vi10 - vi16.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
J.-C. Tardif and M. Talajic
Perindopril and prevention of atrial fibrillation
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E25 - E29.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C.-T. Tsai, D. L. Wang, W.-P. Chen, J.-J. Hwang, C.-S. Hsieh, K.-L. Hsu, C.-D. Tseng, L.-P. Lai, Y.-Z. Tseng, F.-T. Chiang, et al.
Angiotensin II Increases Expression of {alpha}1C Subunit of L-Type Calcium Channel Through a Reactive Oxygen Species and cAMP Response Element-Binding Protein-Dependent Pathway in HL-1 Myocytes
Circ. Res., May 25, 2007; 100(10): 1476 - 1485.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
I. C. Van Gelder
Rhythm control for atrial fibrillation: Non-channel antiarrhythmic drugs are en vogue
Cardiovasc Res, April 1, 2007; 74(1): 8 - 10.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Shiroshita-Takeshita, B. J.J.M. Brundel, B. Burstein, T.-K. Leung, H. Mitamura, S. Ogawa, and S. Nattel
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure
Cardiovasc Res, April 1, 2007; 74(1): 75 - 84.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
C. I Coleman, S. Makanji, J. Kluger, and C M. White
Effect of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on the Frequency of Post-Cardiothoracic Surgery Atrial Fibrillation
Ann. Pharmacother., March 1, 2007; 41(3): 433 - 437.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Shiroshita-Takeshita, M. Sakabe, K. Haugan, J. K. Hennan, and S. Nattel
Model-Dependent Effects of the Gap Junction Conduction-Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs
Circulation, January 23, 2007; 115(3): 310 - 318.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. W. Lee, T. H. Everett IV, D. Rahmutula, J. M. Guerra, E. Wilson, C. Ding, and J. E. Olgin
Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure
Circulation, October 17, 2006; 114(16): 1703 - 1712.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 651 - 745.
[Full Text] [PDF]


Home page
Eur Heart JHome page
N. Dagres, G. Karatasakis, F. Panou, G. Athanassopoulos, T. Maounis, E. Tsougos, K. Kourea, I. Malakos, D. Th. Kremastinos, and D. V. Cokkinos
Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation
Eur. Heart J., September 1, 2006; 27(17): 2062 - 2068.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Osranek, K. Fatema, F. Qaddoura, A. Al-Saileek, M. E. Barnes, K. R. Bailey, B. J. Gersh, T. S.M. Tsang, K. J. Zehr, and J. B. Seward
Left Atrial Volume Predicts the Risk of Atrial Fibrillation After Cardiac Surgery: A Prospective Study
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 779 - 786.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): e257 - e354.
[Full Text] [PDF]


Home page
Exp PhysiolHome page
Y. Kuramochi, X. Guo, D. B. Sawyer, and C. C. Lim
Rapid electrical stimulation induces early activation of kinase signal transduction pathways and apoptosis in adult rat ventricular myocytes
Exp Physiol, July 1, 2006; 91(4): 773 - 780.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. M. Hylek, J. D'Antonio, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan
Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation
Stroke, April 1, 2006; 37(4): 1075 - 1080.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
Eur. Heart J., March 1, 2006; 27(5): 512 - 518.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. Boos, R. A. Anderson, and G. Y.H. Lip
Is atrial fibrillation an inflammatory disorder?
Eur. Heart J., January 2, 2006; 27(2): 136 - 149.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
J. S. Kalus, C. I. Coleman, and C. M. White
The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation
J. Clin. Pharmacol., January 1, 2006; 46(1): 21 - 28.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Bollmann
First comes diagnosis then comes treatment: an underappreciated paradigm in atrial fibrillation management
Eur. Heart J., December 1, 2005; 26(23): 2487 - 2489.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. D.M. Engelmann and J. H. Svendsen
Inflammation in the genesis and perpetuation of atrial fibrillation
Eur. Heart J., October 2, 2005; 26(20): 2083 - 2092.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. Milliez, N. DeAngelis, C. Rucker-Martin, A. Leenhardt, E. Vicaut, E. Robidel, P. Beaufils, C. Delcayre, and S. N. Hatem
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction
Eur. Heart J., October 2, 2005; 26(20): 2193 - 2199.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Nattel
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
Eur. Heart J., October 2, 2005; 26(20): 2079 - 2080.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Anne, R. Willems, T. Roskams, P. Sergeant, P. Herijgers, P. Holemans, H. Ector, and H. Heidbuchel
Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation
Cardiovasc Res, September 1, 2005; 67(4): 655 - 666.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. C. Dudley Jr, N. E. Hoch, L. A. McCann, C. Honeycutt, L. Diamandopoulos, T. Fukai, D. G. Harrison, S. I. Dikalov, and J. Langberg
Atrial Fibrillation Increases Production of Superoxide by the Left Atrium and Left Atrial Appendage: Role of the NADPH and Xanthine Oxidases
Circulation, August 30, 2005; 112(9): 1266 - 1273.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Camm
Atrial fibrillation - an end to the epidemic?
Circulation, August 23, 2005; 112(8): iii - iii.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. S. Healey, A. Baranchuk, E. Crystal, C. A. Morillo, M. Garfinkle, S. Yusuf, and S. J. Connolly
Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis
J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1832 - 1839.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1243 - 1248.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J.-C. Tardif, P. L. L'Allier, P.-F. Keller, and A. Ducharme
Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: A possible contributing mechanism: Reply
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1144 - 1144.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Wachtell, M. Lehto, E. Gerdts, M. H. Olsen, B. Hornestam, B. Dahlof, H. Ibsen, S. Julius, S. E. Kjeldsen, L. H. Lindholm, et al.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 712 - 719.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. G. Bourassa
Angiotensin II inhibition and prevention of atrial fibrillation and stroke
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 720 - 721.
[Full Text] [PDF]


Home page
CirculationHome page
M. Allessie, U. Schotten, S. Verheule, and E. Harks
Gene Therapy for Repair of Cardiac Fibrosis: A Long Way to Tipperary
Circulation, February 1, 2005; 111(4): 391 - 393.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Verma, O. M. Wazni, N. F. Marrouche, D. O. Martin, F. Kilicaslan, S. Minor, R. A. Schweikert, W. Saliba, J. Cummings, J. D. Burkhardt, et al.
Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: An independent predictor of procedural failure
J. Am. Coll. Cardiol., January 18, 2005; 45(2): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. M. Pritchett, D. W. Mahoney, S. J. Jacobsen, R. J. Rodeheffer, B. L. Karon, and M. M. Redfield
Diastolic dysfunction and left atrial volume: A population-based study
J. Am. Coll. Cardiol., January 4, 2005; 45(1): 87 - 92.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Kistler, N. C. Davidson, P. Sanders, S. P. Fynn, I. H. Stevenson, S. J. Spence, J. K. Vohra, P. B. Sparks, and J. M. Kalman
Absence of acute effects of angiotensin II on atrial electrophysiology in humans
J. Am. Coll. Cardiol., January 4, 2005; 45(1): 154 - 156.
[Full Text] [PDF]


Home page
EuropaceHome page
S. G. Williams, D. T. Connelly, M. Jackson, A. Bennett, K. Albouaini, and D. M. Todd
Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
Europace, January 1, 2005; 7(6): 554 - 559.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
S. Nattel
Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?
Can. Med. Assoc. J., September 28, 2004; 171(7): 752 - 753.
[Full Text] [PDF]


Home page
HeartHome page
W Anne, R Willems, N Van der Merwe, F Van de Werf, H Ector, and H Heidbuchel
Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics
Heart, September 1, 2004; 90(9): 1025 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Hanna, S. Cardin, T.-K. Leung, and S. Nattel
Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure
Cardiovasc Res, August 1, 2004; 63(2): 236 - 244.
[Abstract] [Full Text] [PDF]